Xenetic Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $4.43M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 7, 2026 | Before market open | $700.00K | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | $800.00K | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 13, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | $1.00M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | $600.00K | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 19, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 10, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 22, 2024 | Before market open | – | – | – |
Press releases
Announcements Xenetic Biosciences filed with the SEC
Advancing NET - Targeted Therapies for Immune - Driven Diseases and Cancer INVESTOR PRESENTATION SEPTEMBER 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Advancing NET - Targeted Therapies for Immune - Driven Diseases and Cancer INVESTOR PRESENTATION SEPTEMBER 2026
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE DATED AUGUST 7, 2026
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED MAY 13, 2026
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inc. Announces Adjournment of 2025 Annual Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED AUGUST 13, 2025
Results of operations · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE
Results of operations · EX-99.1 to Form 8-K
Xenetic Biosciences, Inc. Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Inc. Extends Research and Development Collaboration with
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Inc. Announces Executive Leadership Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Xenetic Biosciences, Inc. Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Leveraging DNase I to Target Neutrophil Extracellular Traps (NETs) 5
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Reverse Stock Split of Common Stock
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenetic Biosciences, Inc. Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Xenetic Biosciences, Inc. Reports Full Year 2022
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
XENETIC BIOSCIENCES, INC. PRESS RELEASE
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenetic Biosciences, Inc. Expands Oncology Pipeline
Material agreement · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenetic Biosciences, Inc. Reports Full Year
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K